Some GOP House members have voiced support for tax credits that incentivize clean energy production and U.S.-based manufacturing, but the industry is bracing for cuts to incentives and a slowdown in ...
With fewer Part D plans and a $2,000 out-of-pocket cap, beneficiaries must rethink their Medicare drug coverage for 2025.
The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate prices for its costliest ...
19h
The CMS estimated that coverage of the weight-loss drugs will cost the federal government about $25 billion for Medicare and ...
The U.S. pharmaceutical industry is attempting to delay the timeline for Medicare's drug price negotiations following the ...
We need leaders to level with the American people about the challenges ahead — challenges Joe Biden understands well.
A record-low number of Medicare Part D plans could cause greater Medicare Advantage enrollment, which may not be a good thing ...
In one of the Biden administration’s final health policy pushes, the White House unveiled a proposal to ensure Medicare and Medicaid coverage for obesity drugs.
The Centers for Medicare & Medicaid Services Nov. 26 proposed changes to increase oversight of the Medicare Advantage and ...
The proposal would let patients get Wegovy, Ozempic and related drugs for obesity, which Medicare and Medicaid does not cover ...
U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more ...
Biden-Harris administration proposes expanding Medicare and Medicaid coverage for anti-obesity medications, reducing costs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback